| Pavilion At Brmc, The | |
| 200 Pleasant Street, Bradford, Pennsylvania 16701 | |
| (814) 362-8293 | |
| Name | Pavilion At Brmc, The |
|---|---|
| Location | 200 Pleasant Street, Bradford, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 95 |
| Occupancy Rate | 73.79% |
| Medicare ID (CCN) | 395355 |
| Legal Business Name | Olean General Hospital |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1124014691 |
| Organization Name | OLEAN GENERAL HOSPITAL |
| Doing Business As | THE PAVILION AT BRMC |
| Address | 200 Pleasant Street, Bradford, PA 16701 |
| Phone Number | 814-362-8599 |
News Archive
The Food and Drug Administration approved Vitrase (hyaluronidase for injection). Vitrase is an injectable drug approved as an adjunct to (in combination with) other injected drugs to increase their absorption and dispersion. Hyaluronidase has been used most commonly in combination with local anesthetics in the setting of ophthalmic (eye) surgery.
Lumex Instruments' mercury monitor RA-915AM with the new eight sampling line multiplexer was installed at the Hg treatment plant of Minas de Almadén y Arrayanes, S.A., S.M.E (MAYASA).
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.
War is hell, as the old saying goes - with loss of life and limb, destruction of infrastructure and the environment, and devastating costs. Recent biomedical research has shed light on another pernicious consequence of military conflict: psychological and neurological conditions like post-traumatic stress disorder and traumatic brain injury. At the same time, researchers have worked to uncover some of the motives and meanings of war.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The Food and Drug Administration approved Vitrase (hyaluronidase for injection). Vitrase is an injectable drug approved as an adjunct to (in combination with) other injected drugs to increase their absorption and dispersion. Hyaluronidase has been used most commonly in combination with local anesthetics in the setting of ophthalmic (eye) surgery.
Lumex Instruments' mercury monitor RA-915AM with the new eight sampling line multiplexer was installed at the Hg treatment plant of Minas de Almadén y Arrayanes, S.A., S.M.E (MAYASA).
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.
War is hell, as the old saying goes - with loss of life and limb, destruction of infrastructure and the environment, and devastating costs. Recent biomedical research has shed light on another pernicious consequence of military conflict: psychological and neurological conditions like post-traumatic stress disorder and traumatic brain injury. At the same time, researchers have worked to uncover some of the motives and meanings of war.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.77 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.36 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 39.19 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.89 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 11.81 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.51 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 81 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 16.49 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 68.93 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.7 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.77 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 19.78 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 2.14 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 85 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 77.99 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 73.61 | 82.93 |
News Archive
The Food and Drug Administration approved Vitrase (hyaluronidase for injection). Vitrase is an injectable drug approved as an adjunct to (in combination with) other injected drugs to increase their absorption and dispersion. Hyaluronidase has been used most commonly in combination with local anesthetics in the setting of ophthalmic (eye) surgery.
Lumex Instruments' mercury monitor RA-915AM with the new eight sampling line multiplexer was installed at the Hg treatment plant of Minas de Almadén y Arrayanes, S.A., S.M.E (MAYASA).
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.
War is hell, as the old saying goes - with loss of life and limb, destruction of infrastructure and the environment, and devastating costs. Recent biomedical research has shed light on another pernicious consequence of military conflict: psychological and neurological conditions like post-traumatic stress disorder and traumatic brain injury. At the same time, researchers have worked to uncover some of the motives and meanings of war.
› Verified 3 days ago
Pavilion At Brmc, The Location: 200 Pleasant Street, Bradford, Pennsylvania 16701 Phone: (814) 362-8293 | |
Bradford Ecumenical Home, Inc Location: 100 Saint Francis Drive, Bradford, Pennsylvania 16701 Phone: (814) 368-5648 |